CL2011001438A1 - Formulación farmacéutica depot en forma de micropartículas que comprende octreotida o una sal de la misma, y dos polímeros lineales de polilactido-co-glicólido (plgas) diferentes que tienen una proporción molar l:g de 75:25, con viscosidades inherentes diferentes; kit que la comprende, útil en acromegalia, diarrea grave y deposición repentina asociada a tumores malignos. - Google Patents
Formulación farmacéutica depot en forma de micropartículas que comprende octreotida o una sal de la misma, y dos polímeros lineales de polilactido-co-glicólido (plgas) diferentes que tienen una proporción molar l:g de 75:25, con viscosidades inherentes diferentes; kit que la comprende, útil en acromegalia, diarrea grave y deposición repentina asociada a tumores malignos.Info
- Publication number
- CL2011001438A1 CL2011001438A1 CL2011001438A CL2011001438A CL2011001438A1 CL 2011001438 A1 CL2011001438 A1 CL 2011001438A1 CL 2011001438 A CL2011001438 A CL 2011001438A CL 2011001438 A CL2011001438 A CL 2011001438A CL 2011001438 A1 CL2011001438 A1 CL 2011001438A1
- Authority
- CL
- Chile
- Prior art keywords
- different
- acromegaly
- octreotide
- glycolide
- microparticles
- Prior art date
Links
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 title 1
- 206010000599 Acromegaly Diseases 0.000 title 1
- 108010016076 Octreotide Proteins 0.000 title 1
- 241000607479 Yersinia pestis Species 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 230000008021 deposition Effects 0.000 title 1
- 239000011859 microparticle Substances 0.000 title 1
- 229960002700 octreotide Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 229920000642 polymer Polymers 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
- 208000026775 severe diarrhea Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/19—Syringes having more than one chamber, e.g. including a manifold coupling two parallelly aligned syringes through separate channels to a common discharge assembly
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Inorganic Chemistry (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08171712 | 2008-12-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2011001438A1 true CL2011001438A1 (es) | 2011-11-04 |
Family
ID=40520410
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2011001438A CL2011001438A1 (es) | 2008-12-15 | 2011-06-14 | Formulación farmacéutica depot en forma de micropartículas que comprende octreotida o una sal de la misma, y dos polímeros lineales de polilactido-co-glicólido (plgas) diferentes que tienen una proporción molar l:g de 75:25, con viscosidades inherentes diferentes; kit que la comprende, útil en acromegalia, diarrea grave y deposición repentina asociada a tumores malignos. |
Country Status (25)
| Country | Link |
|---|---|
| US (10) | US20100151033A1 (enExample) |
| EP (1) | EP2376070B1 (enExample) |
| JP (1) | JP5721635B2 (enExample) |
| KR (1) | KR101708517B1 (enExample) |
| CN (3) | CN105233251A (enExample) |
| AR (1) | AR074603A1 (enExample) |
| AU (1) | AU2009336718B9 (enExample) |
| BR (1) | BRPI0922607B1 (enExample) |
| CA (1) | CA2746968C (enExample) |
| CL (1) | CL2011001438A1 (enExample) |
| CO (1) | CO6382109A2 (enExample) |
| EC (1) | ECSP11011199A (enExample) |
| ES (1) | ES2602614T3 (enExample) |
| IL (1) | IL213034A (enExample) |
| MA (1) | MA32964B1 (enExample) |
| MX (1) | MX2011006335A (enExample) |
| MY (1) | MY159789A (enExample) |
| NZ (1) | NZ592998A (enExample) |
| PE (1) | PE20110876A1 (enExample) |
| PL (1) | PL2376070T3 (enExample) |
| PT (1) | PT2376070T (enExample) |
| RU (1) | RU2526822C2 (enExample) |
| SG (1) | SG171255A1 (enExample) |
| TN (1) | TN2011000261A1 (enExample) |
| WO (1) | WO2010079047A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20170929T1 (hr) | 2008-09-17 | 2017-09-22 | Chiasma Inc. | Farmaceutski pripravci i odgovarajući postupci za isporuku |
| BR112014028443B1 (pt) * | 2012-05-14 | 2021-01-19 | Teijin Limited | composição estéril esterilizada com radiação |
| EP3125871B1 (en) * | 2014-03-31 | 2020-10-21 | Pharmathen S.A. | Preparation of peptide loaded plga microspheres with controlled release characteristics |
| AU2015360485B2 (en) | 2014-12-10 | 2020-06-25 | Amryt Endo, Inc. | Oral octreotide administered in combination with other therapeutic agents |
| AU2016215350B2 (en) * | 2015-02-03 | 2021-11-25 | Amryt Endo, Inc. | Method of treating diseases |
| CN105963258B (zh) | 2016-04-26 | 2021-01-22 | 广州帝奇医药技术有限公司 | 一种缓释微粒的制备方法 |
| KR102142026B1 (ko) * | 2017-05-31 | 2020-08-06 | 주식회사 대웅제약 | 방출제어가 용이한 서방성 약물 미립자의 제조방법 |
| EP3681471B1 (en) | 2017-09-15 | 2025-03-05 | Oxular Limited | Ophthalmic delivery device |
| JP7704740B2 (ja) | 2019-09-16 | 2025-07-08 | アムジエン・インコーポレーテツド | 薬物送達デバイスの外部滅菌の方法 |
| US11141457B1 (en) | 2020-12-28 | 2021-10-12 | Amryt Endo, Inc. | Oral octreotide therapy and contraceptive methods |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH30995A (en) * | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
| GB9513224D0 (en) * | 1995-06-29 | 1995-09-06 | Sandoz Ltd | Organic compounds |
| BR0315304A (pt) * | 2002-11-06 | 2005-08-16 | Alza Corp | Formulações com depósito para liberação controlada |
| US20040097419A1 (en) * | 2002-11-19 | 2004-05-20 | Holger Petersen | Organic compounds |
| MY158342A (en) * | 2003-11-14 | 2016-09-30 | Novartis Ag | Pharmaceutical composition |
| GB0326602D0 (en) * | 2003-11-14 | 2003-12-17 | Novartis Ag | Organic compounds |
| US7456254B2 (en) * | 2004-04-15 | 2008-11-25 | Alkermes, Inc. | Polymer-based sustained release device |
| US20090092650A1 (en) * | 2004-12-15 | 2009-04-09 | Warren Stephen L | Sustained Delivery Formulations of Octreotide Compounds |
| EP1968549B1 (en) * | 2005-12-22 | 2014-05-14 | Novartis AG | Sustained release formulation comprising octreotide and two or more polylactide-co-glycolide polymers |
-
2009
- 2009-12-11 AR ARP090104820A patent/AR074603A1/es unknown
- 2009-12-11 US US12/635,761 patent/US20100151033A1/en not_active Abandoned
- 2009-12-14 KR KR1020117016340A patent/KR101708517B1/ko not_active Expired - Fee Related
- 2009-12-14 CN CN201510542720.5A patent/CN105233251A/zh active Pending
- 2009-12-14 BR BRPI0922607-9A patent/BRPI0922607B1/pt not_active IP Right Cessation
- 2009-12-14 CN CN2009801503147A patent/CN102245210A/zh active Pending
- 2009-12-14 SG SG2011034345A patent/SG171255A1/en unknown
- 2009-12-14 CA CA2746968A patent/CA2746968C/en not_active Expired - Fee Related
- 2009-12-14 JP JP2011540134A patent/JP5721635B2/ja active Active
- 2009-12-14 ES ES09799316.6T patent/ES2602614T3/es active Active
- 2009-12-14 AU AU2009336718A patent/AU2009336718B9/en not_active Ceased
- 2009-12-14 WO PCT/EP2009/067049 patent/WO2010079047A2/en not_active Ceased
- 2009-12-14 NZ NZ592998A patent/NZ592998A/xx not_active IP Right Cessation
- 2009-12-14 PL PL09799316T patent/PL2376070T3/pl unknown
- 2009-12-14 MY MYPI2011002392A patent/MY159789A/en unknown
- 2009-12-14 EP EP09799316.6A patent/EP2376070B1/en active Active
- 2009-12-14 MX MX2011006335A patent/MX2011006335A/es active IP Right Grant
- 2009-12-14 US US13/133,968 patent/US20110262545A1/en not_active Abandoned
- 2009-12-14 CN CN201510542237.7A patent/CN105031607A/zh active Pending
- 2009-12-14 MA MA34011A patent/MA32964B1/fr unknown
- 2009-12-14 PT PT97993166T patent/PT2376070T/pt unknown
- 2009-12-14 PE PE2011001218A patent/PE20110876A1/es active IP Right Grant
- 2009-12-14 RU RU2011128538/15A patent/RU2526822C2/ru active
-
2011
- 2011-05-19 IL IL213034A patent/IL213034A/en active IP Right Grant
- 2011-05-23 TN TN2011000261A patent/TN2011000261A1/fr unknown
- 2011-06-14 CL CL2011001438A patent/CL2011001438A1/es unknown
- 2011-06-15 CO CO11074834A patent/CO6382109A2/es not_active Application Discontinuation
- 2011-07-13 EC EC2011011199A patent/ECSP11011199A/es unknown
-
2014
- 2014-08-25 US US14/467,212 patent/US20140363513A1/en not_active Abandoned
-
2015
- 2015-12-09 US US14/964,079 patent/US20160089336A1/en not_active Abandoned
-
2017
- 2017-01-10 US US15/402,657 patent/US20170143791A1/en not_active Abandoned
- 2017-10-19 US US15/788,047 patent/US20180036230A1/en not_active Abandoned
-
2019
- 2019-03-14 US US16/352,986 patent/US20190209462A1/en not_active Abandoned
-
2021
- 2021-02-09 US US17/171,836 patent/US20210161806A1/en not_active Abandoned
-
2023
- 2023-04-27 US US18/308,597 patent/US20240082148A1/en not_active Abandoned
-
2024
- 2024-08-08 US US18/797,888 patent/US20250205147A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2011001438A1 (es) | Formulación farmacéutica depot en forma de micropartículas que comprende octreotida o una sal de la misma, y dos polímeros lineales de polilactido-co-glicólido (plgas) diferentes que tienen una proporción molar l:g de 75:25, con viscosidades inherentes diferentes; kit que la comprende, útil en acromegalia, diarrea grave y deposición repentina asociada a tumores malignos. | |
| CL2008000510A1 (es) | Compuestos conjugados farmaco-ligandos, que se unen a citotoxinas potentes; composicion farmaceutica; y uso para retardar o detener el crecimiento de un tumor en un mamifero. | |
| MX355294B (es) | Artículos para el cuidado personal que tienen composiciones para el cuidado personal que tienen múltiples zonas amoldables. | |
| EP2039729A3 (en) | Anisotropic magnetic flakes | |
| EA201890417A1 (ru) | Генетически кодируемые, внутренне неупорядоченные полимеры-"невидимки" для доставки и способы их применения | |
| AR059667A1 (es) | Montaje de desgaste | |
| WO2003105035A8 (en) | Application level security | |
| EP3261146A3 (en) | Organic electroluminescent materials and devices | |
| EA200601776A1 (ru) | Метадоновые композиции местного действия и способы их применения | |
| CL2010000188A1 (es) | Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso. | |
| ECSP13012534A (es) | Composición farmacéutica | |
| CY1112738T1 (el) | Μια συνδυασμενη συνθεση που περιεχει ιβουπροφαινη και παρακεταμολη | |
| EA201071248A1 (ru) | Дизамещенные фталазиновые антагонисты пути hedgehog | |
| CL2008003006A1 (es) | Uso de ester metilico del acido (-)-(3ar,4s,7ar)-4-hidroxi-4-m-toliletinil-octahidro-indol-1-carboxilico en base libre o en forma de sal para el tratamiento, prevencion o retraso de la progresion de la disquinesia de parkinson asociada a l-dopa; uso de la composicion farmaceutica; uso de una composicion que ademas comprende l-dopa. | |
| MX2009012421A (es) | Inhibicion de metastasis de tumor por anticuerpos anti neuropilina 2. | |
| CL2008000304A1 (es) | Compuestos derivados de 1-oxa-3-azaespiro[4.5]decan-2-ona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de un trastorno de la alimentacion, obesidad, depresion. | |
| HRP20090010A2 (en) | Use of thymosin alpha 1 for preparing a medicament for the treatment of stage iv malignant melanoma | |
| MX2007007355A (es) | 5-(2,2-dimetil-ciclopropil)-3-metil-pen-2-en nitrilo como fragancia y sabor. | |
| DE602007009204D1 (de) | Von kollagen typ iv abgeleitetes cyclopeptid mit antikrebswirkung | |
| AR046373A1 (es) | Composiciones antitranspirantes | |
| ITRM20050478A1 (it) | Apparato per l'applicazione contemporanea della carbossiterapia e della mesoterapia. | |
| ATE457010T1 (de) | Behälter mit verschluss | |
| CN203504114U (zh) | 线体保护装置 | |
| AR117204A1 (es) | MOLÉCULAS DE ARNm DE VARIANTE KRAS | |
| RU2004131357A (ru) | Поршневое кольцо |